DermTech (NASDAQ: DMTK)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.890 | -1.010 | -0.1200 | ||||
REV | 3.750M | 3.718M | -32.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of DermTech (NASDAQ: DMTK) through any online brokerage.
Other companies in DermTech’s space includes: Impel Pharmaceuticals (NASDAQ:IMPL), Inozyme Pharma (NASDAQ:INZY), MoonLake (NASDAQ:MLTX), Humanigen (NASDAQ:HGEN) and Gritstone Bio (NASDAQ:GRTS).
The latest price target for DermTech (NASDAQ: DMTK) was reported by Stephens & Co. on Friday, January 7, 2022. The analyst firm set a price target for 0.00 expecting DMTK to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The stock price for DermTech (NASDAQ: DMTK) is $6.5 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for DermTech.
DermTech’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for DermTech.
DermTech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.